DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.27%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$423M
AUM Growth
+$423M
(+1.1%)
Cap. Flow
-$19.4M
Cap. Flow
% of AUM
-4.58%
Top 10 Holdings %
Top 10 Hldgs %
48.91%
Holding
89
New
6
Increased
19
Reduced
26
Closed
5
Top Buys
| 1 |
Lexeo Therapeutics
LXEO
|
$2.27M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$1.57M |
| 3 |
IDEAYA Biosciences
IDYA
|
$1.56M |
| 4 |
Ascendis Pharma
ASND
|
$1.28M |
| 5 |
Structure Therapeutics
GPCR
|
$1.27M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$7.9M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$4.3M |
| 3 |
Viking Therapeutics
VKTX
|
$4.02M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$2.51M |
| 5 |
TSVT
2seventy bio
TSVT
|
$1.99M |
Sector Composition
| 1 | Healthcare | 86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $39.7M | 9.37% | 401,505 -43,500 | -10% | -$4.3M |
|
2
Stereotaxis
STXS
$261M
| $27.9M | 6.59% | 13,680,554 | – | – |
|
3
Revolution Medicines
RVMD
$7.1B
| $23.5M | 5.55% | 517,994 +6,100 | +1% | +$277K |
|
4
Cytokinetics
CYTK
$4.23B
| $21M | 4.97% | 398,100 | – | – |
|
5
Merus
MRUS
$4.98B
| $20.6M | 4.87% | 412,573 +3,128 | +0.8% | +$156K |
|
6
AtriCure
ATRC
$1.84B
| $18M | 4.25% | 641,673 +2,500 | +0.4% | +$70.1K |
|
|
7
IDEAYA Biosciences
IDYA
$2.15B
| $14.9M | 3.53% | 471,410 +49,197 | +12% | +$1.56M |
|
8
iShares Biotechnology ETF
IBB
$5.6B
| $14.9M | 3.53% | 102,500 | – | – |
|
|
9
Ascendis Pharma
ASND
$11.8B
| $13.4M | 3.16% | 89,572 +8,600 | +11% | +$1.28M |
|
10
Axogen
AXGN
$743M
| $13.1M | 3.1% | 935,894 | – | – |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $11.3M | 2.66% | 121,763 +17,000 | +16% | +$1.57M |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $10.8M | 2.55% | 273,739 | – | – |
|
13
Day One Biopharmaceuticals
DAWN
$769M
| $10.5M | 2.47% | 750,363 +83,900 | +13% | +$1.17M |
|
|
14
Syndax Pharmaceuticals
SNDX
$1.41B
| $10.1M | 2.4% | 526,702 -130,372 | -20% | -$2.51M |
|
15
Biohaven
BHVN
$1.63B
| $9.35M | 2.21% | 187,130 -31,600 | -14% | -$1.58M |
|
16
Tandem Diabetes Care
TNDM
$845M
| $8.66M | 2.05% | 204,208 | – | – |
|
17
KalVista Pharmaceuticals
KALV
$678M
| $8.38M | 1.98% | 723,678 -83,295 | -10% | -$965K |
|
18
Neurocrine Biosciences
NBIX
$13.8B
| $8.02M | 1.89% | 69,615 -2,000 | -3% | -$230K |
|
19
Kura Oncology
KURA
$686M
| $7.98M | 1.89% | 408,368 -15,132 | -4% | -$296K |
|
|
20
Viking Therapeutics
VKTX
$3.04B
| $7.95M | 1.88% | 125,616 -63,501 | -34% | -$4.02M |
|
21
Edgewise Therapeutics
EWTX
$1.51B
| $6.08M | 1.44% | 227,906 -62,291 | -21% | -$1.66M |
|
22
UroGen Pharma
URGN
$900M
| $5.83M | 1.38% | 458,915 -10,085 | -2% | -$128K |
|
23
BioCryst Pharmaceuticals
BCRX
$1.74B
| $5.07M | 1.2% | 667,000 -37,500 | -5% | -$285K |
|
24
DexCom
DXCM
$29.5B
| $4.39M | 1.04% | 65,552 | – | – |
|
25
Keros Therapeutics
KROS
$618M
| $4.28M | 1.01% | 73,754 +6,000 | +9% | +$348K |
|